Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905270 | 0.91 | TSHR (0.36) | TSHRSMN1; SMN2PPARDTP53TDP1 | |
| SCHEMBL4637563 | 0.78 | PPARD (0.35) | TSHRSMN1; SMN2PPARDTP53TDP1 | |
| SCHEMBL10590583 | 0.75 | TSHR (0.41) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL1683251 | 0.73 | TSHR (0.37) | TSHRSMN1; SMN2PPARDTP53TDP1 | |
| SCHEMBL10128728 | 0.72 | TSHR (0.40) | TSHRPPARDTP53TDP1 | |
| SCHEMBL18048500 | 0.72 | PPARD (0.32) | TSHRPPARD | |
| SCHEMBL25463304 | 0.71 | TSHR (0.39) | TSHRPPARDTP53TDP1 | |
| SCHEMBL11430886 | 0.71 | TP53 (0.41) | TSHRSMN1; SMN2PPARDTP53TDP1 | |
| Trifluoroacetic Acid SCHEMBL3432138 | 0.71 | S1PR1 (0.46) | TSHRPPARDS1PR1S1PR3S1PR2 | |
| SCHEMBL2079486 | 0.71 | TSHR (0.39) | TSHRSMN1; SMN2PPARDTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101291903-B | Novel unsaturated fatty hydroxy acid derivatives and the dermocosmetologic use thereof | FABRE PIERRE DERMO COSMETIQUE | 2014-09-10 | — | — | CN | disclosed |
| US-8158811-B2 | Unsaturated fatty hydroxy acid derivatives and the dermocosmetologic use thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2012-04-17 | — | — | US | disclosed |
| US-7928254-B2 | Method for preparing unsaturated fatty hydroxyacids | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2011-04-19 | — | — | US | disclosed |
| US-20090238784-A1 | Novel Unsaturated Fatty Hydroxy Acid Derivatives and the Dermocosmetologic Use Thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20080281114-A1 | Novel Method for Preparing Unsaturated Fatty Hydroxyacids | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2008-11-13 | — | — | US | disclosed |
| CN-101291903-A | Novel unsaturated fatty hydroxy acid derivatives and the dermocosmetologic use thereof | FABRE PIERRE DERMO COSMETIQUE (FR) | 2008-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238784-A1 | Novel Unsaturated Fatty Hydroxy Acid Derivatives and the Dermocosmetologic Use Thereof | ELOVL3, FFAR3, FASN | TSHR 1800/4885SMN1; SMN2 3627/4885PPARD 66/4885 |
| US-20080281114-A1 | Novel Method for Preparing Unsaturated Fatty Hydroxyacids | FASN, ELOVL1, ELOVL3 | TSHR 3172/4885SMN1; SMN2 3431/4885PPARD 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.